US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Bayer A.G.

13.51

-0.1200-0.88%

Volume:1.25M

Turnover:17.01M

Market Cap:53.09B

PE:-228.53

High:13.85

Open:13.81

Low:13.48

Close:13.63

52wk High:13.98

52wk Low:5.30

Shares:3.93B

Float Shares:3.93B

Volume Ratio:0.61

T/O Rate:0.03%

Dividend:0.03

Dividend Rate:0.23%

EPS(TTM):-0.0591

EPS(LYR):-0.6723

ROE:-0.57%

ROA:3.06%

PB:1.51

PE(LYR):-20.09

Loading ...

Overview Company News Filings

Bayer’s Sepsis–DIC Study Wraps Up: What the New Data Effort Means for BAYRY Investors

Bayer Cleared to Offer Stryax After EPA Registers Dicamba Herbicides

Bayer's Asundexian Data Are Better Than Hoped -- Market Talk

Bayer says Asundexian showed 26% reduction in stroke in Phase III study

European Pharmaceutical Stocks Follow U.S. Peers Down -- Market Talk

Bayer investing over C$45M to build canola research, development facility

Dow Jones Top Company Headlines at 7 AM ET: Micron to Buy Taiwan Plant for $1.8 Billion | Bayer ...

Bayer Expected to Open Higher on U.S. Supreme Roundup Challenge -- Market Talk

Bayer ‘welcomes’ Supreme Court review of Durnell litigation

U.S. Supreme Court to hear Bayer’s appeal of Roundup lawsuits, Bloomberg says

Bayer Shares Surge as Partner Forecasts Sales Growth for Prostate-Cancer Drug

Bayer to acquire AT-01 and AT-05 from Attralus, terms undisclosed

European Pharma Stocks Follow Asian, U.S. Peers Higher -- Market Talk

Bayer sues COVID vaccine makers over mRNA technology

Bayer stock has its best day in 17 years after support from Trump's solicitor general

White House Backs Bayer's Bid for Supreme Court Review in Roundup Case

Stocks to Watch Monday: Alibaba, Tesla, Alphabet, Bayer -- WSJ

Bayer's stock is jumping on secondary stroke drug's trial success

Bayer Sees Positive Results in Study for Asundexian as Stroke Treatment

Bayer’s Asundexian met primary efficacy, safety endpoints in Phase III study

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BAYRY/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BAYRY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BAYRY\",,,,,undefined,":{"symbol":"BAYRY","market":"US","secType":"STK","nameCN":"Bayer A.G.","latestPrice":13.51,"timestamp":1770928920000,"preClose":13.63,"halted":0,"volume":1245921,"delay":15,"changeRate":-0.008804108584005942,"floatShares":3929259738,"shares":3929696328,"eps":-0.059118,"marketStatus":"Trading","change":-0.12,"latestTime":"02-12 15:42:00 EST Delay","open":13.81,"high":13.85,"low":13.48,"amount":17013975.728382,"amplitude":0.027146,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.059118,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770930000000},"marketStatusCode":2,"adr":0,"adrRate":0.25,"exchange":"OTCQX","adjPreClose":13.63,"volumeRatio":0.60596},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BAYRY\",,,,,undefined,":{"symbol":"BAYRY","floatShares":3929259738,"roa":"3.06%","roe":"-0.57%","lyrEps":-0.672343,"volumeRatio":0.60596,"shares":3929696328,"dividePrice":0.031,"high":13.85,"amplitude":0.027146,"preClose":13.63,"low":13.48,"week52Low":5.3,"pbRate":"1.51","psRate":"0.98","week52High":13.98,"institutionHeld":0.0018,"latestPrice":13.51,"eps":-0.059118,"divideRate":0.002295,"volume":1245921,"delay":15,"ttmEps":-0.059118,"open":13.81,"prevYearClose":10.82,"prevWeekClose":13.41,"prevMonthClose":13.15,"prevQuarterClose":10.82,"fiveDayClose":13.65,"twentyDayClose":12.09,"sixtyDayClose":8.19},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BAYRY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-13","symbol":"BAYRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"","actualEps":null},{"date":"2025-04-29","symbol":"BAYRY","amount":0.030365,"announcedDate":"2025-04-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-29","defaultRemindTime":1745933400000,"name":"Bayer A.G.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-12","payableDate":"2025-04-29","currency":"USD","dateTimestamp":1745899200000,"payDate":"2025-05-12"},{"market":"US","date":"2024-11-12","symbol":"BAYRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"","actualEps":null},{"date":"2024-08-06","symbol":"BAYRY","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1722974400000,"name":null,"time":"Post Market","dateTimestamp":1722916800000,"actualEps":null},{"date":"2024-05-14","symbol":"BAYRY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715673600000,"name":null,"time":"","dateTimestamp":1715659200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BAYRY\",market:\"US\",,,undefined,":[{"executeDate":"2016-04-27","recordDate":"2016-04-29","paymentDate":"2016-05-12","value":2.091196,"currency":"USD"},{"executeDate":"2019-04-29","recordDate":"2019-04-30","paymentDate":"2019-05-13","value":0.550569,"currency":"USD"},{"executeDate":"2020-04-29","recordDate":"2020-04-30","paymentDate":"2020-05-14","value":0.535933,"currency":"USD"},{"executeDate":"2021-04-28","recordDate":"2021-04-29","paymentDate":"2021-05-10","value":0.407111,"currency":"USD"},{"executeDate":"2022-05-02","recordDate":"2022-05-03","paymentDate":"2022-05-16","value":0.549114,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BAYRY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.3333,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":3,"updateTime":1763096400000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BAYRY\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610952840","title":"Bayer’s Sepsis–DIC Study Wraps Up: What the New Data Effort Means for BAYRY Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2610952840","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610952840?lang=en_us&edition=fundamental","pubTime":"2026-02-12 00:30","pubTimestamp":1770827450,"startTime":"0","endTime":"0","summary":"Bayer AG ($BAYRY) announced an update on their ongoing clinical study. Bayer is running an exploratory study called “Exploratory Study to Investiga...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bayers-sepsis-dic-study-wraps-up-what-the-new-data-effort-means-for-bayry-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bayers-sepsis-dic-study-wraps-up-what-the-new-data-effort-means-for-bayry-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ISBC","BAYRY"],"gpt_icon":0},{"id":"2609171045","title":"Bayer Cleared to Offer Stryax After EPA Registers Dicamba Herbicides","url":"https://stock-news.laohu8.com/highlight/detail?id=2609171045","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609171045?lang=en_us&edition=fundamental","pubTime":"2026-02-07 07:44","pubTimestamp":1770421440,"startTime":"0","endTime":"0","summary":"Bayer can now offer its Stryax herbicide following government approval.The Environmental Protection Agency registered low-volatility dicamba herbicides in 34 states, which opens the door for Bayer to launch Stryax, a restricted use pesticide, the company said Friday.The German pharmaceuticals and agricultural products maker now plans to seek state approvals, said Ty Witten, head of Bayer's commercial stewardship in crop science.Stryax helps manage glyphosate-resistant broadleaf weeds and other tough to control weeds. It also offers up to 14 days of soil activity in certain weeds, helping farmers keep fields clean, Bayer said.The pesticide was designed as an additional herbicide option for in-crop use with XtendFlex soybeans, Roundup Ready 2 Xtend soybeans and cotton with XtendFlex technology.The registration allows for the use of approved low-volatility dicamba herbicides in-crop up to 7 days pre-harvest in XtendFlex cotton and up through R1 in XtendFlex soybeans.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Bayer Cleared to Offer Stryax After EPA Registers Dicamba Herbicides","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2609568197","title":"Bayer's Asundexian Data Are Better Than Hoped -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2609568197","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609568197?lang=en_us&edition=fundamental","pubTime":"2026-02-06 16:15","pubTimestamp":1770365700,"startTime":"0","endTime":"0","summary":"0815 GMT - Bayer released data for its asundexian drug candidate for stroke prevention that seem better than hoped and support an optimistic view on the medicine's potential, analysts at Morgan Stanley say. The German pharma-to-agriculture group said asundexian reduced by 26% the risk of recurrent stroke in patients who experienced an initial stroke compared to placebo. The efficacy results are very strong and came alongside a more favorable safety profile than expected, the analysts say in a research note. The data represent a bull-case outcome for asundexian, they add. Morgan Stanley estimates the drug could generate annual peak sales of 4 billion euros in secondary stroke prevention. Bayer shares rise 0.3%. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Bayer's Asundexian Data Are Better Than Hoped -- Market Talk","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1244550577.SGD","LU1720051108.HKD","LU2089284900.SGD","LU1244550494.USD","LU1732799900.SGD","LU0795875086.SGD","LU1162221912.USD","LU1074936037.SGD","LU0267386448.USD","LU0557290698.USD","BK4585","LU1363072403.SGD","LU2347655156.SGD","LU2089283258.USD","LU2357305700.SGD","LU0320765646.SGD","LU1989772840.SGD","IE00BKVL7J92.USD","LU1548497426.USD","LU0098860793.USD","LU1989772923.USD","BK4504","BK4581","BK4534","LU0006306889.USD","LU0225283273.USD","LU0158827781.USD","BK4007","LU1720051017.SGD","LU2023251221.USD","LU2028103732.USD","BK4588","LU1791710400.SGD","IE00BZ1G4Q59.USD","BK4516","LU1732800096.USD","LU0158827948.USD","BK4127","LU0234570918.USD","LU0882574139.USD","LU2111349929.HKD","LU0106261372.USD","LU1244550221.USD","LU0528227936.USD","LU0106831901.USD","LU0971096721.USD","LU0912757837.SGD","BAYRY","LU0795875169.SGD","LU2133065610.SGD"],"gpt_icon":0},{"id":"2609588206","title":"Bayer says Asundexian showed 26% reduction in stroke in Phase III study","url":"https://stock-news.laohu8.com/highlight/detail?id=2609588206","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609588206?lang=en_us&edition=fundamental","pubTime":"2026-02-06 01:20","pubTimestamp":1770312017,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) presented the results from the global, pivotal Phase III OCEANIC-STROKE study evaluating the use of its investigational, once-daily, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-says-asundexian-showed-26-reduction-in-stroke-in-phase-iii-study-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-says-asundexian-showed-26-reduction-in-stroke-in-phase-iii-study-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4134","III","BAYRY","BK4007"],"gpt_icon":0},{"id":"2606910792","title":"European Pharmaceutical Stocks Follow U.S. Peers Down -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2606910792","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606910792?lang=en_us&edition=fundamental","pubTime":"2026-01-28 18:17","pubTimestamp":1769595420,"startTime":"0","endTime":"0","summary":"Copyright (c) 2026 Dow Jones & Company, Inc.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","NVO","IE00BFXG1179.USD","BK4599","LU1093756325.SGD","SDZNY","BK4588","RHHBY","IE00BZ1G4Q59.USD","BK4585","LU1093756168.USD","BAYRY","BK4007","IE00BKVL7J92.USD","LU0154236417.USD","GSK","03165"],"gpt_icon":1},{"id":"2606736970","title":"Bayer investing over C$45M to build canola research, development facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2606736970","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606736970?lang=en_us&edition=fundamental","pubTime":"2026-01-28 00:05","pubTimestamp":1769529916,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) Crop Science announced an unprecedented C$45M+ investment to strengthen Canada’s leadership in canola innovation by establishing a ca...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-investing-over-c45m-to-build-canola-research-development-facility-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-investing-over-c45m-to-build-canola-research-development-facility-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2604013807","title":"Dow Jones Top Company Headlines at 7 AM ET: Micron to Buy Taiwan Plant for $1.8 Billion | Bayer ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2604013807","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604013807?lang=en_us&edition=fundamental","pubTime":"2026-01-19 20:00","pubTimestamp":1768824000,"startTime":"0","endTime":"0","summary":"The Boise, Idaho-based company plans to acquire the Taiwanese chip-making site to meet surging demand for memory-storage products.Bayer Shares Rise After U.S Supreme Court Agrees to Review Roundup Case. The conglomerate is challenging litigation that claims its flagship weedkiller Roundup causes cancer.Are Megabanks Next in the Crackdown on Stock Buybacks?After the Trump administration's threats to defense contractors and home builders, the risk has jumped for bank shareholders.Commercial Builders Are Losing Their Appetite to Build Anything but Data Centers. Spending on data-center construction is expected to rise by 23% in 2026, while the building of offices, hotels and apartments is seen declining slightly.Elliott Reiterates Opposition to Revised Offer for Toyota Industries. The U.S. activist investor said a stand-alone plan would offer a path to a much higher valuation.Taiwan's Flagship Chip Maker Charts a Future Beyond Taiwan. TSMC has for decades provided a \"Silicon Shield\" to its","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"9acab31d521d02d4d6fe40c91ed92c46","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2211815571.USD","LU2286300806.USD","LU1852331112.SGD","BAYRY","BK4605","IE00B19Z3581.USD","IE00BZ18W456.USD","LU0203345920.USD","LU2089985449.USD","BK4590","MULL","IE00BMQBXF63.USD","IE00BZ18W340.USD","LU2458330169.SGD","LU0642271901.SGD","IE00B7SZLL34.SGD","BK4533","BK4585","LU2250418816.HKD","LU2931357623.SGD","MUU","LU0056508442.USD","LU0889565833.HKD","LU0082616367.USD","LU0081259029.USD","LU1366333091.USD","GB00BDT5M118.USD","LU1316542783.SGD","MUD","LU0274383776.USD","BK4141","BK4527","BK4512","MU","LU0792757196.USD","LU1323610961.USD","BK4144","LU0203347892.USD","BK4543","BK4553","LU2360106780.USD","BK4532","LU2458330243.SGD","BK4581","LU0109392836.USD","LU2048586759.USD","LU0719512351.SGD","BK4566","BK4554","BK4575","LU0157215616.USD","LU1267930813.SGD","BK4561","BK4579","LU0127658192.USD","LU0889566641.SGD","LU1803068979.SGD","IE00B19Z3B42.SGD","IE0002270589.USD"],"gpt_icon":1},{"id":"2604790023","title":"Bayer Expected to Open Higher on U.S. Supreme Roundup Challenge -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2604790023","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604790023?lang=en_us&edition=fundamental","pubTime":"2026-01-19 14:24","pubTimestamp":1768803840,"startTime":"0","endTime":"0","summary":"0623 GMT - Bayer is expected to open higher after the U.S. Supreme Court agreed to hear its challenge to litigation which claims its flagship weedkiller Roundup causes cancer. The court on Friday said it would take up an appeal from the German company. \"We expect a positive share price response,\" Jefferies analysts write. The decision by the court is incrementally positive and could affect the tens of thousands of remaining claims, they said. The company booked litigation provisions alongside third-quarter results. The decision by the court also improves Bayer's negotiating position should it wish to pursue a settlement, the analysts add. Shares closed Friday at 41.515 euros.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BAYRY"],"gpt_icon":0},{"id":"2604916420","title":"Bayer ‘welcomes’ Supreme Court review of Durnell litigation","url":"https://stock-news.laohu8.com/highlight/detail?id=2604916420","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604916420?lang=en_us&edition=fundamental","pubTime":"2026-01-17 04:20","pubTimestamp":1768594816,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) said the U.S. Supreme Court today announced that it will review the Durnell Roundup case. “Monsanto petitioned the court to hear Durn...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-welcomes-supreme-court-review-of-durnell-litigation-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-welcomes-supreme-court-review-of-durnell-litigation-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2604915765","title":"U.S. Supreme Court to hear Bayer’s appeal of Roundup lawsuits, Bloomberg says","url":"https://stock-news.laohu8.com/highlight/detail?id=2604915765","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604915765?lang=en_us&edition=fundamental","pubTime":"2026-01-17 03:40","pubTimestamp":1768592415,"startTime":"0","endTime":"0","summary":"The U.S. Supreme Court will hear Bayer’s (BAYRY) appeal challenging thousands of lawsuits that claim its top-selling Roundup weed killer causes can...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/u-s-supreme-court-to-hear-bayers-appeal-of-roundup-lawsuits-bloomberg-says-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/u-s-supreme-court-to-hear-bayers-appeal-of-roundup-lawsuits-bloomberg-says-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2603611422","title":"Bayer Shares Surge as Partner Forecasts Sales Growth for Prostate-Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2603611422","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603611422?lang=en_us&edition=fundamental","pubTime":"2026-01-14 22:02","pubTimestamp":1768399320,"startTime":"0","endTime":"0","summary":"Shares in Bayer jumped 6% after Finnish pharmaceutical company Orion predicted strong growth for darolutamide, a prescription prostate-cancer medication on which the two companies partner.Bayer stock gained 5.8%, or 2.26 euros, to 41.2 euros in early afternoon European trading Wednesday. Shares in Orion also leapt on the announcement, gaining 12%. The Helsinki-listed company is the biggest riser in the Europe-wide Stoxx 600 index.Bayer and Orion partnered in 2014 to develop darolutamide, with Bayer funding development while Orion handled the drug's manufacturing. Bayer is responsible for taking the drug to market globally.Darolutamide is Orion's biggest drug by far and its main profit-driver, the company said. Sales of the drug could exceed 1 billion euros  in the future, it added.Orion guided for net group sales for this year of between 1.9 billion euros and 2.1 billion euros and for operating profit of 550 million euros to 750 million euros.The company hasn't released 2025 earnings, ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Bayer Shares Surge as Partner Forecasts Sales Growth for Prostate-Cancer Drug","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2602107395","title":"Bayer to acquire AT-01 and AT-05 from Attralus, terms undisclosed","url":"https://stock-news.laohu8.com/highlight/detail?id=2602107395","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602107395?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:16","pubTimestamp":1768223800,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) and Attralus announced that the companies have entered into definitive agreements for Bayer to acquire AT-01 and AT-05, two investiga...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-to-acquire-at-01-and-at-05-from-attralus-terms-undisclosed-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-to-acquire-at-01-and-at-05-from-attralus-terms-undisclosed-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2601587170","title":"European Pharma Stocks Follow Asian, U.S. Peers Higher -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2601587170","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601587170?lang=en_us&edition=fundamental","pubTime":"2026-01-07 18:32","pubTimestamp":1767781920,"startTime":"0","endTime":"0","summary":"Copyright (c) 2026 Dow Jones & Company, Inc.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","BK4578","BK4007","LU0208291251.USD","IE0002141913.USD","BAYRY","IE00B2B36J28.USD","BK4588","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0211331839.USD","LU0070302665.USD","IE0009355771.USD","LU0320765489.SGD","NVS","IE00BJJMRZ35.SGD","BK4585","BK4532"],"gpt_icon":0},{"id":"2601846229","title":"Bayer sues COVID vaccine makers over mRNA technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2601846229","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601846229?lang=en_us&edition=fundamental","pubTime":"2026-01-07 07:00","pubTimestamp":1767740445,"startTime":"0","endTime":"0","summary":"UPDATE 1-Bayer sues COVID vaccine makers over mRNA technologyAdds links to lawsuits in paragraphs 2 and 3, Moderna response and requests for defendant comments in paragraph 4By Blake Brittain. Bayer's complaints add to a web of patent lawsuits over the blockbuster COVID shots, which include an ongoing lawsuit filed by Moderna against Pfizer in 2022.Bayer was not involved in developing COVID vaccines and does not make or sell any version of them. It asked the courts for an unspecified amount of monetary damages and said it was not seeking to block the companies from manufacturing their vaccines.Pfizer and BioNTech earned more than $3.3 billion in revenue from global sales of their vaccine Comirnaty in 2024, while Moderna earned $3.2 billion from its Spikevax, according to company reports, a fraction of their sales at the height of the pandemic.Johnson & Johnson stopped selling its COVID vaccine in the United States in 2023.Bayer's lawsuits said Monsanto scientists pioneered technology i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL6N3Y7174:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2750360997.AUD","LU2592432038.USD","LU0203345920.USD","LU1057294990.SGD","LU0868494617.USD","LU1894683264.USD","LU2129689605.HKD","IE00BJJMRZ35.SGD","LU1496350502.SGD","LU0225284248.USD","LU2471134796.USD","IE00B42XCP33.USD","BK4532","BK4588","LU0114720955.EUR","SG9999013999.USD","LU0792757196.USD","IE00BJT1NW94.SGD","LU1244550221.USD","LU0683600562.USD","LU2471134879.HKD","LU2471134952.CNY","LU0289739699.SGD","LU0345770308.USD","LU1929549753.HKD","IE00BZ1G4Q59.USD","LU0466842654.USD","IE00BFXG1179.USD","BK4504","LU1883839398.USD","LU0985481810.HKD","IE00BVYPNW00.USD","IE00B3T34201.USD","LU0124676726.USD","LU1162221912.USD","SG9999003800.SGD","IE000M9KFDE8.USD","LU1221951046.USD","LU0795875086.SGD","BK4568","LU1674673691.USD","BK4139","LU1778281490.HKD","LU2112291526.USD","LU1066051225.USD","LU0795875169.SGD","LU0321505868.SGD","LU2089984988.USD","IE00BVYPNV92.GBP","LU0345769128.USD","IE00BGHQF631.EUR","LU1074936037.SGD","LU1221951129.SGD","LU1244550577.SGD","SG9999001176.SGD","IE0034235303.USD","LU1061106388.HKD","LU0882574055.USD","LU1196500208.SGD","LU1732800096.USD","LU1914381329.SGD","IE00B19Z3581.USD","LU2468319806.SGD","IE00B1BXHZ80.USD","IE0002141913.USD","LU1023059063.AUD","BK4550","IE00BFTCPJ56.SGD","LU1718418525.SGD","IE00BSNM7G36.USD","IE00B3PB1722.GBP","LU0321505439.SGD","MRNA","BK4585","LU0070217475.USD","LU2602419157.SGD","LU0234570918.USD","LU0320765646.SGD","IE0009355771.USD","LU0170899867.USD","BK4007","LU1894683348.USD","LU2471134523.USD","LU0225771236.USD","LU2505996509.AUD","LU1261432733.SGD","IE0002270589.USD","SG9999001176.USD","LU1506573853.SGD","LU1244550494.USD","LU2129689431.USD","LU2430703178.SGD","BAYRY","LU0640476718.USD","LU2430703251.USD","LU1430594728.SGD","LU1032466523.USD","BK4551","BK4533","LU0432979614.USD","LU0345770993.USD","BK4501","BNTX","LU1032955483.USD","BK4559","BK4548","LU0787776722.HKD","LU1066053197.SGD","LU1585245621.USD","BK4592","JNJ","LU0306806265.USD","LU2133065610.SGD","SG9999001440.SGD","IE00BDGV0183.EUR","BK4581","LU0912757837.SGD","LU1066051498.USD","LU0456855351.SGD","LU1935042991.SGD","LU0234572021.USD","LU2750360641.GBP","LU2430703095.HKD","LU0889566641.SGD","LU1280957306.USD","SG9999002232.USD","BK4534","LU2129689514.USD","BK4599","IE00B4R5TH58.HKD","LU0122379950.USD","IE00B2B36J28.USD","IE00BLSP4452.SGD","LU2505996681.GBP","LU0058720904.USD","IE00BKVL7J92.USD","LU1732799900.SGD","IE00B19Z3B42.SGD","LU0345769631.USD","SG9999011175.SGD","LU1066051811.HKD","IE00BBT3K403.USD","LU1267930813.SGD","LU2347655156.SGD","SGXZ57979304.SGD","LU0203347892.USD","IE00BN8TJ469.HKD","LU0985320562.USD","IE00BLSP4239.USD","SG9999002224.SGD","IE00B7SZLL34.SGD","LU1059921491.USD","LU0306807586.USD","LU0689626769.HKD","LU1674673428.USD","LU0098860793.USD"],"gpt_icon":1},{"id":"2588803554","title":"Bayer stock has its best day in 17 years after support from Trump's solicitor general","url":"https://stock-news.laohu8.com/highlight/detail?id=2588803554","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588803554?lang=en_us&edition=fundamental","pubTime":"2025-12-02 16:52","pubTimestamp":1764665520,"startTime":"0","endTime":"0","summary":"A file photo taken on September 1, 2019 shows Roundup weedkiller on sale that is the subject of thousands of lawsuits in the U.S. Bayer stock rose on Tuesday after the U.S. solicitor general backed the company in an amicus brief to the Supreme Court.Bayer shares rose as much as 15% on Tuesday after the U.S. solicitor general backed the company's bid to get the Supreme Court to curtail litigation alleging its Roundup pesticide causes cancer.Analysts said the move will support the German company's attempts to resolve litigation around what's called glyphosate by the end of 2026. Solicitor General D. John Sauer on Monday said the Environmental Protection Agency repeatedly has stated that glyphosate  is not likely to be carcinogenic in humans and that the agency has repeatedly approved Roundup labels without cancer warnings.Bayer welcomed the support in the lawsuit, Monsanto Co. vs. Durnell, and the issue of whether a federal insecticide rule preempts state law. Bayer said \"tens of thousan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BAYRY"],"gpt_icon":0},{"id":"2588700087","title":"White House Backs Bayer's Bid for Supreme Court Review in Roundup Case","url":"https://stock-news.laohu8.com/highlight/detail?id=2588700087","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588700087?lang=en_us&edition=fundamental","pubTime":"2025-12-02 15:27","pubTimestamp":1764660420,"startTime":"0","endTime":"0","summary":"Bayer said it welcomed the U.S. Solicitor General's support for a Supreme Court review of a case that could curtail longrunning litigation regarding its Roundup pesticide.The German life-sciences company said the government's support would be significant as the Court weighs its petition, arguing that federal pesticide law preempts state-level failure-to-warn claims. This could limit tens of thousands of lawsuits alleging that the company's Roundup weed-killer causes cancer.Solicitor General D. John Sauer in a brief said that \"[the Environmental Protection Agency] has repeatedly determined that glyphosate is not likely to be carcinogenic in humans, and the agency has repeatedly approved Roundup labels that did not contain cancer warnings.\". Bayer previously stated that it aims to significantly contain Roundup litigation by the end of 2026.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"White House Backs Bayer's Bid for Supreme Court Review in Roundup Case","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2585685064","title":"Stocks to Watch Monday: Alibaba, Tesla, Alphabet, Bayer -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2585685064","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585685064?lang=en_us&edition=fundamental","pubTime":"2025-11-24 17:50","pubTimestamp":1763977800,"startTime":"0","endTime":"0","summary":"Alibaba : The Chinese e-commerce leader said its Qwen artificial-intelligence app drew more than 10 million downloads in the first week after a relaunch. Shares jumped 4.7% in Hong Kong.Tyson Foods : America's largest meat supplier plans to close a major beef-processing plant, as a cattle shortage squeezes the industry.Anglo American : Following fresh talks, BHP  said it wouldn't pursue a takeover of its London-listed rival, clearing the way for Anglo to close a merger with Teck Resources .Comcast : Universal Pictures movie \"Wicked: For Good\" opened in U.S. and Canadian theaters with ticket sales worth an estimated $150 million, one of the biggest domestic debuts of 2025. Comcast owns Universal.This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL .","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09988","ALBmain","LU0345774631.USD","CMCSA","LU2720916845.USD","LU2764263203.CNY","USJW.SI","89988","IE00BMPRXR70.SGD","AKZOY","LU0203201768.USD","BABA","IE00B3S45H60.SGD","IE00BZ199S13.USD","LU1044874839.SGD","LU2326559502.SGD","IE00BQXX3D17.EUR","LU0345781412.USD","LU0499858438.USD","LU2191332357.HKD","TSN","LU0359202008.SGD","BK4007","LU0326950275.SGD","LU1303224171.USD","LU1069344957.HKD","TSYW.SI","LU1221951046.USD","LU0203202063.USD","BK1142","LU0594300419.USD","LU2039709279.SGD","LU2125910849.SGD","HBBD.SI","LU0348788117.USD","LU0648948544.HKD","LU0370786039.SGD","BK4077","BK4588","LU2362541513.USD","LU2125154935.USD","LU0039217434.USD","LU2764263039.SGD","TSLL","LU1037948541.HKD","TSLA","TECK","BAYRY"],"gpt_icon":1},{"id":"2585468890","title":"Bayer's stock is jumping on secondary stroke drug's trial success","url":"https://stock-news.laohu8.com/highlight/detail?id=2585468890","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585468890?lang=en_us&edition=fundamental","pubTime":"2025-11-24 17:47","pubTimestamp":1763977620,"startTime":"0","endTime":"0","summary":"Bayer shares rose on Monday after the company said a late-stage trial of a stroke drug met its goals.Bayer stock jumped on Monday after the German healthcare company said a late-stage stroke drug trial achieved its goals.Bayer didn't give too much away: on Sunday the company said a Phase III trial with 12,300 patients of an oral drug called Asundexian significantly reduced the risk of a secondary stroke, and that there also was no increase in the risk of major bleeding.It will present detailed results at an upcoming scientific congress.Bayer says that of the 12 million people who suffer a stroke each year, 20% to 30% will be a recurrent stroke, and that one in five stroke survivors have another one in five years. The drug works by inhibiting what's called Factor XIa, which can lead to blood clotting.\"This is a material de-risking event for Bayer's pipeline, validating FXIa inhibition as a differentiated anticoagulation approach,\" said analysts at Jefferies.Bayer shares  jumped 11%, add","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2585445503","title":"Bayer Sees Positive Results in Study for Asundexian as Stroke Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2585445503","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585445503?lang=en_us&edition=fundamental","pubTime":"2025-11-24 14:46","pubTimestamp":1763966760,"startTime":"0","endTime":"0","summary":"Bayer said it had positive results in late-stage clinical trials for a drug preventing stroke, after a previous study with the same drug failed to reduce blood-clot formation.The German pharmaceutical company said Sunday that the once-daily 50mg asundexian medication, when combined with antiplatelet therapy, lowered the risk of stroke in patients during the study. It did so without causing major bleeding, a side effect of other blood thinning medications, Bayer said.The drug blocks Factor XIa, a protein that contributes to blood clotting, Bayer said.Bayer said it met the primary objective of the Phase 3 Oceanic-Stroke trial.It halted a Phase 3 clinical trial last year testing the effectiveness of the experimental drug for stroke and systemic embolism prevention. At the time, the trial's failure dealt a blow to Bayer's pharmaceutical division, as it was expected to bring the division back to growth.The company said it would work with global health authorities as it prepares marketing au","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2585438825","title":"Bayer’s Asundexian met primary efficacy, safety endpoints in Phase III study","url":"https://stock-news.laohu8.com/highlight/detail?id=2585438825","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585438825?lang=en_us&edition=fundamental","pubTime":"2025-11-24 05:30","pubTimestamp":1763933413,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) announced positive topline results from the global Phase III study OCEANIC-STROKE, with its investigational, once daily, oral FXIa in...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayers-asundexian-met-primary-efficacy-safety-endpoints-in-phase-iii-study-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayers-asundexian-met-primary-efficacy-safety-endpoints-in-phase-iii-study-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["III","BAYRY","BK4007","BK4134"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":34,"code":"91000000","status":"200"}]}}